louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04115904: Acute Pain Rate of Single Versus Two-visit Root Canal Treatment of Teeth With Necrotic Pulps
Official title: Acute Pain Rate of Single Versus Two-visit Root Canal Treatment of Teeth With Necrotic Pulp and Apical Periodontitis: A Multicenter Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Pain, Postoperative
Lead sponsor: Universidad Autonoma de Baja California
Sponsor class: OTHER
First posted: 2019-10-04
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 110 teeth with a diagnosis of pulp necrosis and apical radiolucency at the apex.Working length was established with EAL and confirmed radiographically. M4system with Flex-R files were used to complete canal preparation. Level ofdiscomfort were recorded and cases with severe postoperative pain
Primary purpose: TREATMENT

Brief summary: Aim to compare acute pain rate after single-visit ortwo-visits treatment of teeth with necrotic pulp and apical periodontitis .90 teeth with a diagnosis of pulp necrosis and apical radiolucency at the apex.Working length was established with EAL and confirmed radiographically. Flex-R files were used to complete canal preparation. Level ofdiscomfort were recorded and cases with acute postoperative pain.

Detailed description: 90 teeth with a diagnosis of pulp necrosis and apical radiolucency at the apex.Working length was established with EAL and confirmed radiographically. M4system with Flex-R files were used to complete canal preparation. Level ofdiscomfort were recorded and cases with severe postoperative pain and/orswelling were classified as acute pain.

Eligibility criteria: Inclusion Criteria: a) Radiographic evidence of apical periodontitis (minimum size ≥2.0mm x 2.0 mm) and a diagnosis of pulpal necrosis confirmed by negativeresponse to hot and cold tests and b) Need for retreatment. Thermal pulptesting was performed by the author, and radiographic interpretation wasverified by one certified oral surgeon

-

Exclusion Criteria:

* patients without inclusion requirements or failure to obtain patient ́sauthorization. Patients, were excluded if they were younger than 18 yearsold, pregnant, had a positive history of antibiotic use within the past month,suffered from diabetes, or other systemic diseases. Teeth with periodontalpockets deeper than 4 mm also were excluded of the study

Primary outcomes:
measure: Pain intensity measure with general pain scale
timeFrame: a week
Secondary outcomes:
Other outcomes:
Locations:
city: Tijuana
country: Mexico
facility: Jorge Paredes Vieyra
state: Baja California
city: Tijuana
country: Mexico
facility: Jorge Paredes Vieyra
state: Baja Califronia
city: Tijuana
country: Mexico
facility: Jose Clemente Orozco
state: BC
city: Tijuana
country: Mexico
facility: Jose Clemente
state: BC
Study officials:
References:
Clinical trial NCT05870904: Dry Needling & Trigger Point Compression Release in Neck Pain
Official title: A Randomized Clinical Trial To Review The Effectiveness Of Dry Needling Versus Trigger Point Compression Release Among Patients With Neck Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Trigger Point Pain, Myofascial
Neck Muscle Issue
Muscle Tightness
Neckache
Keywords: Dry Needling
Ischemic Compression
Neck Pain
Lead sponsor: Health Education Research Foundation (HERF)
Sponsor class: OTHER
First posted: 2023-05-23
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized control trial was conducted to investigate the efficacy of trigger point dry needling which is a modern treatment intervention compared with ischemic compression release in the patients having neck pain due to myofascial trigger points.

Detailed description: Many treatment protocols have been used in the clinical arena for the improvement of neck pain but un-availability of follow-up studies and lack of evidence of modern treatment interventions are few shortcomings a researcher faces. Thus, a need stands up to address these perspectives for newer treatment strategies. This randomized control trial is conducted to investigate the efficacy of trigger point dry needling which is a modern treatment intervention compared with ischemic compression release in the patients having neck pain due to myofascial trigger points. Findings of this research will assist in creating awareness about better treatment intervention for trigger point release among medical community.

Eligibility criteria: Inclusion Criteria:

* Patients between the age group of 20 to 40 years.
* Both Male and female patients.
* Patients presenting with neck pain due to MTrP's.
* The presence of a palpable taut band in the neck region.
* Patients reporting typically referred pain pattern of the MTrP in response to compression.

Exclusion Criteria:

* Patients with any associated comorbidities such as hypertension and diabetes.
* Patients with known history of fibromyalgia syndrome, whiplash injury, cervical spine surgery fracture and cervical radiculopathy.
* Patients with any systemic disease such as rheumatism and tuberculosis or cervical myelopathy and multiple sclerosis.
* Patients with history of myofascial trigger point therapy one month prior to enrollment.
* Patients with non-cooperative attitude, fear or any contraindications to needling.

Primary outcomes:
measure: Change in Pain assessed through Visual Analogue Pain Scale
timeFrame: Data was Collected at Baseline and after week 1,2 & 3.
measure: Change in degree of disability assessed through Northwick Park Neck Pain Questionnaire.
timeFrame: Data was Collected at Baseline and after week 1,2 & 3.
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Bashir Institute of Health Sciences,Bashir General & Dental Hospital
Study officials:
References:
Clinical trial NCT00479804: Non-Invasive Determination of Cardiac Output by Inertgas Rebreathing Method
Official title: Non-Invasive Determination of Cardiac Output by the Inertgas Rebreathing Method Compared With Magnetic Resonance Tomography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Diseases
Keywords: indication for CMR
Lead sponsor: Universitätsmedizin Mannheim
Sponsor class: OTHER
First posted: 2007-05-28
Enrollment: 311
Sex: ALL
Minimum age (years): 14
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Study population: Consecutive patients with indication for CMR

Brief summary: The cardiac output (CO) is an important parameter in the diagnosis and therapy of cardiac diseases. The current standard methods for the determination of the CO, however, are either invasive (e.g. right heart catheterization) or technically expendable and expensive (magnetic resonance tomography, MRT). The traditional non-invasive methods of determining the CO by rebreathing of carbon dioxide are easily carried out but suffer from methodical inaccuracies. Therefore the aim of the study at hand was to evaluate a new method for determining the CO by means of the inert gas rebreathing method.


Eligibility criteria: Inclusion Criteria:

* Indication for CMR
* Ability of following instructions for rebreathing test

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Mannheim
country: Germany
facility: 1st Department of Medicine, University Hospital Mannheim
state: Baden-Württemberg
Study officials:
affiliation: 1st Department of Medicine
name: Joachim Saur, Dr.
role: STUDY_DIRECTOR
affiliation: 1st Deparment of Medicine
name: Jens Kaden, Dr.
role: STUDY_CHAIR
References:
Clinical trial NCT01636804: Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads
Official title: Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads: Impact on Electrophysiological Profile
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Left Ventricular Pacing Leads
Keywords: Quicksite
Quickflex
St. Jude Medical
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2012-07-10
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients that received either Quicksite or Quickflex leads at the University of Kansas Hospital

Brief summary: On April 2, 2012 the manufacturer of the Quicksite® and Quickflex® leads, St. Jude Medical, released a voluntary medical device advisory regarding these leads' potential for problems with the silicone insulation covering one end of the lead, where it meets another section of the lead which is coated with a different insulating material (polyurethane). There has been a voluntary suspension of sales of these leads.

There are approximately 179,000 of the above leads implanted worldwide with an estimated 101,000 leads currently in service (59,000 in US). There have been 39 confirmed cases of the conductor portion of the lead becoming exposed from the silicone insulation (externalization), and the rate of occurrence of this type of problem is conservatively estimated at less than one percent. However, a review done by St. Jude Medical of returned Quicksite® and Quickflex® leads and available X-ray and fluoroscopic (x-ray movie) images of patients with these leads (from 1,219 patients) revealed a higher rate of 3-4%. It is presumed that there are patients whose leads have not yet been affected by this problem, but whose leads may show signs of structural changes on x-ray or fluoroscopy. This study seeks to determine what structural changes may be occurring in these leads, what signs might predict these changes, and what impact these changes may have on the lead and its performance.


Eligibility criteria: Inclusion Criteria:

* Patient that received Quicksite or Quickflex lead at the University of Kansas Hospital

Exclusion Criteria:

* Not willing to consent to data collection

Primary outcomes:
measure: Evaluate the mechanical/structural abnormalities in implanted St Jude Medical QuickSite® and QuickFlex® left ventricular (LV) pacing leads
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: University of Kansas Medical Center
name: Dhanunjaya Lakkireddy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00873301: The Effectiveness of Vestibulectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vulvodynia
Keywords: vulvodynia
vestibulectomy
surgery
vestibulitis
Lead sponsor: Western Galilee Hospital-Nahariya
Sponsor class: OTHER_GOV
First posted: 2009-04-01
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Women with vulvodynia will fill out a questionnaire and undergo a gynecological examination before and 6 months after vestibulectomy. The investigators hypothesize that pain will decrease.


Eligibility criteria: Inclusion Criteria:

* vulvodynia, scheduled for vestibulectomy

Primary outcomes:
measure: pain
timeFrame: 6 months following surgery
Secondary outcomes:
measure: sexual function
timeFrame: 6 months afater surgery
Other outcomes:
Locations:
city: Nahariya
country: Israel
facility: Western Galilee Hospital- Nahariya
Study officials:
References:
Clinical trial NCT01046201: Pediatric Obesity Research Registry
Official title: Pediatric Obesity Research Registry
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Obesity
Lead sponsor: Phoenix Children's Hospital
Sponsor class: OTHER
First posted: 2010-01-11
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese patients up to age 18 years treated at Phoenix Children's Hospital

Brief summary: The Pediatric Obesity Research Registry will function to collect and catalog historical and medical chart related clinical data of patients presenting with pediatric obesity and who agree to participate.

Detailed description: Individuals between age 1 and 18 years who present to the endocrinology clinic for management of elevated BMI/Obesity (Body Mass Index≥95th percentile of age and gender), will be given the opportunity to read the consent form, have any questions/ concerns addressed prior to obtaining informed consent from the research team (consisting of the PI and the Co-investigators) who are also part of the child's clinical care team. The child's clinician will introduce the study to the parents. The Investigator will obtain written informed consent from the child's parents. The clinical care team/research registry investigators will address any questions and concerns prior to obtaining written informed consent and any future questions and concerns. In this manner, Patients seen at the Phoenix Children's Hospital (PCH) Division of Endocrinology and Diabetes with an obesity diagnosis will be asked to provide their written informed consent to allow their past, current and future identifiable medical record information related to their obese condition to be placed in the Pediatric Obesity Research Registry.

For individuals who respond to Potential advertisement or who contact the research team over the phone, a verbal explanation will be given over the phone and an offer to send a copy of the consent via mail/fax/email, and if interested scheduling a follow up appointment. At the clinic visit, the above noted procedure will be followed.

Eligibility criteria: Inclusion Criteria:

* Individuals between age 1 and 18 years who present to the endocrinology clinic for management of elevated BMI/Obesity
* Individuals between age 1 and 18 years who respond to advertisement or who contact the research team over the phone, for management of elevated BMI/Obesity (Body Mass Index ≥ 95th percentile of age and gender)

Exclusion Criteria:

* A Body Mass Index less than 95th percentile of age and gender

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Phoenix Children's Hospital
state: Arizona
Study officials:
affiliation: Phoenix Children's Hospital
name: Donnie P. Wilson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01178801: Sharable Knowledge Mining Platform
Official title: Sharable Knowledge Mining Platform for Clinical Data Extraction, and Medical Knowledge and Mining Services Sharing
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Cancer
Keywords: liver cancer
data mining
knowledge discovering
The clinical data of the patients with liver cancer.
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2010-08-10
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with liver cancer. (ICD9 Code is 155.0)

Brief summary: As a result of increasing adoption of health information systems in hospitals, more and more health records can be gathered and accumulated in the healthcare data repository. For this reason, the opportunity of analyzing and mining the healthcare data for quality improvement is increasing and becoming more and more important.

The purpose of the project is to gather the clinical data relevant to liver cancer, and adopt the knowledge discovery and mining modules in information technology (IT) for analyzing and discovering the knowledge from the gathered clinical data.

We can analyze the gathered clinical data for comparing the outcomes of different treatment strategies, finding out new diagnosis and staging criteria and factors, and other hidden knowledge included in the clinical data.

Afterwards, the discovered results and the mining algorithms can be shared though the sharable knowledge mining platform provided by our project.


Eligibility criteria: Inclusion Criteria:

* Clinical data of patients with liver cancer. (ICD9 Code is 155.0)
* Males and females

Primary outcomes:
measure: the relationship between the clinical data and the decision of treatment strategies
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University
Study officials:
affiliation: National Taiwan University,Graduate Institute of Biomedical Electronics
name: Feipei Lai, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT03937401: Oxytocin in MRI-HIFU
Official title: Use of Oxytocin in MRI-HIFU Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Fibroid
Adenomyosis
Keywords: oxytocin
MRI-HIFU
fibroid
adenomyosis
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2019-05-03
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing MRI-HIFU -treatment
* Patients assessed for suitability to MRI-HIFU treatment
* willingness to participate in trial

Exclusion Criteria:

* Known allergy to Syntocinon/oxytocin
* Elevated blood pressure
* ischemic heart disease
* Long QT- interval

Primary outcomes:
measure: NPV
timeFrame: up to one year
measure: duration of MRI-HIFU
timeFrame: up to one year
measure: UFS-Qol
timeFrame: 12 months after HIFU treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
References:
citation: Otonkoski S, Sainio T, Komar G, Suomi V, Saunavaara J, Blanco Sequeiros R, Perheentupa A, Joronen K. Oxytocin selectively reduces blood flow in uterine fibroids without an effect on myometrial blood flow: a dynamic contrast enhanced MRI evaluation. Int J Hyperthermia. 2020;37(1):1293-1300. doi: 10.1080/02656736.2020.1846792.
Clinical trial NCT00940901: Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Official title: Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Sickle Cell Disease
Priapism
Keywords: priapism
sickle cell disease
sildenafil
phosphodiesterase type 5 inhibitor
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2009-07-17
Enrollment: 13
Sex: MALE
Minimum age (years): 14
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research is being done to evaluate if the phosphodiesterase type 5 (PDE5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (SCD).

Detailed description: The proposed research is designed to investigate the utility of continuous, long-term PDE 5 inhibitor therapy as an intervention for recurrent ischemic priapism, a disorder of non-willful, excessive penile erection, in patients with SCD. Although precise prevalence figures are not available, priapism in SCD is highly prevalent and thought to afflict approximately 40% of males, based on available literature. Additionally, the disorder exacts devastating consequences, including erectile tissue necrosis, erectile dysfunction, and psychological distress. Management of this disorder remains challenging because the mechanisms underlying priapism are incompletely understood.

Eligibility criteria: Inclusion Criteria:

* Ages 14 to 45, inclusive
* Episodes of prolonged penile erection in the absence of sexual interest or desire, with an average frequency of at least twice weekly, when averaged over the previous four weeks
* Able to provide informed consent or assent

Exclusion Criteria:

* Use of chronic nitrates or recreational use of nitrate containing products
* Use of a PDE5 (phosphodiesterase type 5)inhibitor within the previous two weeks
* Alcohol use exceeding two standard drinks daily
* Hypersensitivity to sildenafil
* Estimated glomerular filtration rate \<50ml/min
* Known cirrhosis
* Retinitis pigmentosa
* Necessary use of a P450 3A4 inhibitor (a drug which can increase plasma levels of sildenafil when taken together)

Primary outcomes:
measure: Greater Than or Equal to a 50% Reduction in Priapic Episodes
timeFrame: change between baseline and 8 weeks post intervention
measure: Greater Than or Equal to a 50% Reduction in Priapic Episodes
timeFrame: change between 8 weeks post intervention and 16 weeks post intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Hospital
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Arthur L. Burnett, MD, MBA
role: PRINCIPAL_INVESTIGATOR
References: